Pharmacologically Induced Sex Hormone Fluctuation Effects on Resting-State Functional Connectivity in a Risk Model for Depression: A Randomized Trial.

Fisher PM, Larsen CB, Beliveau V, Henningsson S, Pinborg A, Holst KK, Jensen PS, Svarer C, Siebner HR, Knudsen GM, Frokjaer VG

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology21 Sept 2016Cited by 35 (Europe PMC)

PMID27649641PMCIDPMC5399242DOI10.1038/npp.2016.208PepBankPUB-27649641

Source link PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialMechanism
In healthy women, goserelin did not significantly affect resting-state functional connectivity in any tested seed versus placebo.
In plain wordsIn healthy women, goserelin did not significantly change resting brain connectivity compared with placebo.
Peptide
Goserelin
Outcome
No significant changeResting-state functional connectivity
Study
n = 58
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
GnRHa intervention did not significantly affect rs-FC in any seeds.
1 context sentence(design, population, supporting numbers)
Summary · context
We induced a biphasic ovarian sex hormone fluctuation using the gonadotropin-releasing hormone agonist (GnRHa) goserelin to determine, with a randomized placebo-controlled design, intervention effects on or GnRHa-provoked depressive symptoms associations with change in resting-state functional conne…
Report a problemFND-2764964101
02HumanObservational studyMechanism
In goserelin-treated healthy women, emerging depressive symptoms were positively associated with amygdala-right temporal cortex connectivity changes.
In plain wordsIn women given goserelin, emerging depression symptoms were linked to increased connectivity between the amygdala and right temporal cortex.
Peptide
Goserelin
Outcome
IncreaseDepressive symptoms and amygdala-right temporal connectivity
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Considering the GnRHa group only, the emergence of depressive symptoms following intervention was positively associated with amygdala-right temporal cortex and negatively associated with hippocampus-cingulate rs-FC.
1 context sentence(design, population, supporting numbers)
Summary · context
We induced a biphasic ovarian sex hormone fluctuation using the gonadotropin-releasing hormone agonist (GnRHa) goserelin to determine, with a randomized placebo-controlled design, intervention effects on or GnRHa-provoked depressive symptoms associations with change in resting-state functional conne…
Report a problemFND-2764964102
03HumanObservational studyMechanism
In goserelin-treated healthy women, emerging depressive symptoms were negatively associated with hippocampus-cingulate connectivity changes.
In plain wordsIn women given goserelin, emerging depression symptoms were linked to decreased connectivity between the hippocampus and cingulate.
Peptide
Goserelin
Outcome
DecreaseDepressive symptoms and hippocampus-cingulate connectivity
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Considering the GnRHa group only, the emergence of depressive symptoms following intervention was positively associated with amygdala-right temporal cortex and negatively associated with hippocampus-cingulate rs-FC.
1 context sentence(design, population, supporting numbers)
Summary · context
We induced a biphasic ovarian sex hormone fluctuation using the gonadotropin-releasing hormone agonist (GnRHa) goserelin to determine, with a randomized placebo-controlled design, intervention effects on or GnRHa-provoked depressive symptoms associations with change in resting-state functional conne…
Report a problemFND-2764964103
04HumanObservational studyMechanism
In goserelin-treated women, connectivity changes marginally mediated the association between estradiol decrease and depressive symptom increase (p=0.07).
In plain wordsIn women given goserelin, brain connectivity changes marginally mediated the link between lower estradiol and increased depression symptoms.
Peptide
Goserelin
Outcome
Not applicableConnectivity mediation of estradiol-depression association
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Mediation test p-value
0.07
rs-FC changes mediating estradiol decrease and depressive symptom increase, GnRHa group
Source sentences
Summary
A test for mediation suggested that rs-FC changes in these networks marginally mediated the association between decrease in estradiol and increase in depressive symptoms in the GnRHa group (p=0.07).
1 context sentence(design, population, supporting numbers)
Summary · context
We induced a biphasic ovarian sex hormone fluctuation using the gonadotropin-releasing hormone agonist (GnRHa) goserelin to determine, with a randomized placebo-controlled design, intervention effects on or GnRHa-provoked depressive symptoms associations with change in resting-state functional conne…
Report a problemFND-2764964104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02661789

Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression

Gitte Moos Knudsenn = 63Jan 2011 to Dec 2012

Postpartum Depression · Major Depressive Disorder · Postpartum Psychosis · Menopause · Neurodegeneration · Schizophrenia

Trial page ClinicalTrials.govUpdated 22 Jan 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.